Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data

Drugs in R and D

Volumn 14, Issue 4, 2014, Pages 301-308

  Murai, Kazuki ^a   Katsuno, Tomoyuki ^a   Miyagawa, Jun ichiro ^a   Matsuo, Toshihiro ^a   Ochi, Fumihiro ^a   Tokuda, Masaru ^a   Kusunoki, Yoshiki ^a   Miuchi, Masayuki ^a   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL;

ABDOMINAL DISCOMFORT; ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CALORIC RESTRICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; FUNCTION TEST; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; JAPANESE (PEOPLE); MALE; MEAL TOLERANCE TEST; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CONCENTRATION-TIME CURVE; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FOOD; POSTPRANDIAL STATE; SECRETION (PROCESS);

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FOOD; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SITAGLIPTIN PHOSPHATE;

EID: 84919448533     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-014-0072-6     Document Type: Article

References (20)

1. Japanese Ministry of Health, Labour and Welfare. National Health and Nutrition Survey, 2007 [in Japanese]. http://www.mhlw.go.jp/bunya/kenkou/eiyou09/dl/01-kekka.pdf. Accessed Aug 2014.
2. International Diabetes Federation. IDF diabetes atlas. 5th ed. Brussels: International Diabetes Federation; 2011.
3. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
4. Herman GA, Mistry GC, Yi B, Bergman AJ, Wang AQ, Zeng W, et al. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol. 2011;71:429–36.
5. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study Group. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95:e20–2.
6. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79:291–8.
7. Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57:383–94.
8. Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J. 2013;60:733–42.
9. Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J. 2011;35:159–65.
10. Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:2818–26.
11. Katayama Y, Taniguchi T, Okuyama K, Fujimoto G, Ishii M, Ito M, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, a dipeptidyl peptidase-4 inhibitor, following repeated oral administration in healthy Japanese adult men [in Japanese]. J New Rem Clin. 2011;60:1139–59.
12. Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14:161–8.
13. Ohkura T, Fujioka Y, Sumi K, Nakanishi R, Shiochi H, Yamamoto N, et al. Sitagliptin improves the impaired acute insulin response during a meal tolerance test in Japanese patients with type 2 diabetes mellitus: a small-scale real-world study. Diabetes Ther. 2014;5:285–97.
14. Bosco D, Armanet M, Morel P, Niclauss N, Sgroi A, Muller YD, et al. Unique arrangement of α- and β-cells in human islets of Langerhans. Diabetes. 2010;59:1202–10.
15. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51:2263–70.
16. Tornehave D, Kristensen P, Rømer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem. 2008;56:841–51.
17. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612–9.
18. Aoki K, Masuda K, Miyazaki T, Togashi Y, Terauchi Y. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J. 2010;57:667–72.
19. Nagai E, Katsuno T, Miyagawa J, Konishi K, Miuchi M, Ochi F, et al. Incretin responses to oral glucose load in Japanese non-obese healthy subjects. Diabetes Ther. 2011;2:20–8.
20. Miuchi M, Miyagawa J, Konishi K, Nagai E, Kitamura N, Yano Y, et al. Morphometric analysis of pancreatic α-cells in Japanese non-obese patients with type 2 diabetes mellitus [poster no. 1946-P]. Diabetes. 2011;60 Suppl. 1:A525.